Add Row
Add Element
Add Element
cropper
update

AI GROWS YOUR BUSINESS

cropper
update
Add Element
  • AI update for local business on Facebook
    update
  • AI update for local business on X
    update
  • Dylbo digital media Google business profile
    update
  • Dylbo digital media on LinkedIn
    update
  • update
  • DYLBO digital media on YouTube
    update
  • DYLBO digital media on Instagram
    update
  • Home
  • Categories
    • AI Simplified
    • Tool Talk
    • Success Stories
    • Step-by-Step
    • Future Ready
    • Expert Opinions
    • Money Matters
Add Row
Add Element
May 02.2025
2 Minutes Read

Eli Lilly CEO Speaks on National Security and Drug Tariffs: A Crucial Response

Serious man discussing national security concerns over essential drugs.

National Security in Pharmaceuticals: Eli Lilly On the Frontline

As national conversations around drug tariffs heat up, Eli Lilly CEO Dave Ricks emphasizes the company's readiness to address national security concerns linked to essential medications. In a recent interview, Ricks expressed that the company is prepared to support the U.S. if the government needs additional manufacturing capacity for older medicines. With the Trump administration investigating the implications of pharmaceutical imports on national safety, Ricks highlighted the importance of having vital drugs readily available.

Understanding the Impact of Tariffs on the Drug Market

The looming threat of tariffs on imports, especially aimed at older generic medications primarily produced in countries like India and China, has raised eyebrows across the pharmaceutical landscape. Ricks acknowledged the seriousness of these concerns but remains unsure if tariffs provide a viable solution. "Bringing that capacity back, so in case of emergency, we have the stock, we have the supply – that's a valid thing," he stated, underlining the need for a reliable supply chain.

The Role of Eli Lilly in an Evolving Market

In light of these developments, Eli Lilly stands at a crossroads where it could shape future policies in the pharmaceutical industry. By potentially reshoring production, they not only address security concerns but could also gain a competitive edge. Businesses in similar industries should take note of Eli Lilly’s proactive stance, as it reflects a crucial trend toward ensuring domestic supply chains during uncertain times.

A Community Approach to Health Security

Ricks’ approach resonates beyond corporate interests. In an age where the health landscape is constantly changing, engaging the community and its leaders can bridge the gap between policy, public health, and industry standards. As business leaders and managers consider their roles in these discussions, fostering this dialogue may lead to innovative strategies for a healthier and more resilient society.

Expert Opinions

16 Views

0 Comments

Write A Comment

*
*
Related Posts All Posts
07.13.2025

Why FDA's Drug Affordability Decision Matters for Future Approvals

Update Understanding FDA's New Focus on Drug Affordability The Food and Drug Administration (FDA) is making a notable shift in its approach to drug approvals. According to Dr. Marty Makary, the agency will now take drug affordability into account when granting new priority vouchers aimed at speeding up treatment approvals. This is a significant change, as previous criteria focused more on the support for U.S. national interests without explicitly addressing pricing. The Importance of Affordable Medications In an era where healthcare costs are a growing concern, affordability is a central issue for many Americans. By considering this factor, the FDA acknowledges the necessity of ensuring that new treatments are not only quickly available but also accessible to those who need them. This initiative aligns with a broader goal of the current administration to lower drug prices amid rising healthcare costs. Balancing Speed and Affordability While speeding up the review process is vital for patient access to potentially life-saving medications, the challenge lies in balancing this urgency with price considerations. Typically, drug pricing is established post-approval, which may complicate the FDA's ability to effectively evaluate affordability before a product hits the market. Implications and Future of Drug Approvals The introduction of drug affordability into the approval process is unprecedented, and it raises several questions. How will the FDA evaluate the affordability of new medications? What metrics will be used? As the agency implements this new approach, there may be varying perspectives and expectations among stakeholders within the industry. Experts Weigh In: Perspectives on FDA's Decision Many industry experts believe that focusing on affordability can have long-term benefits. They argue that by prioritizing cost-effective treatments, the FDA can encourage pharmaceutical companies to innovate responsibly, ensuring that future drug developments are both effective and financially feasible for consumers. As these developments unfold, business leaders, healthcare professionals, and policymakers alike need to stay informed. The intersection of drug development speed and affordability could reshape the pharmaceutical landscape, ultimately impacting communities nationwide.

07.13.2025

Superman's Box Office Success: What It Means For DC Films

Update Superman's Box Office TriumphWarner Bros.' latest superhero flick, Superman, recently soared to impressive heights, raking in $22.5 million during its Thursday night previews. This remarkable achievement marked the third-best Thursday performance among DC superhero films, showcasing the strong interest from audiences following its marketing buzz.Setting New RecordsThe film not only broke records for early sales but also set a new benchmark for Superman films, outpacing previous records held by titles like Man of Steel. With this encouraging start, analysts expect the film to hit between $130 to $140 million over the entire opening weekend, aligning its performance with successful DC films such as The Batman, which grossed $134 million last year.High Stakes for New DC EraAs industry experts pointed out, the anticipated success of Superman is particularly significant in light of a new creative direction spearheaded by James Gunn and Peter Safran, raising questions about the future of the DC Universe. As Paul Dergarabedian from Comscore noted, the film carries immense expectations, positioning itself as a critical component of the evolving superhero narrative.The Connection with AudiencesThis launch is not just about numbers; it's an emotional connection that Superman has fostered with fans over generations. Engaging storytelling, well-developed characters, and a nostalgic appeal are at the core of this project, making its box office performance a reflection of audience sentiment. With such a strong opening, it will be fascinating to see how Superman will influence the future of DC films and audience engagement strategies moving forward.As you watch Superman take flight, consider how powerful storytelling can impact your own narratives, both personally and professionally.

07.13.2025

FDA’s New Vouchers Now Consider Drug Affordability: A Game Changer

Update FDA's New Focus: Affordable Drugs for All In a significant shift, the Food and Drug Administration (FDA) will now consider drug affordability when issuing new vouchers that expedite the approval process for certain treatments. This decision, announced by Commissioner Dr. Marty Makary, marks a critical step in prioritizing not just speed, but also the economic impact of medications on Americans. Understanding the Voucher System The FDA has unveiled a national priority voucher program aimed at reducing drug review times to just one or two months for select companies deemed to support U.S. national interests. This initiative, however, previously did not explicitly account for drug prices in its criteria. As part of ongoing efforts to lower prescription costs, affordability has now been highlighted as a national priority. The Importance of Drug Affordability Lowering drug prices is essential, especially as consumers feel the pinch of rising healthcare expenses. This development comes at a time when companies face scrutiny over pricing strategies, which often determine launch costs only after a drug receives approval. In this context, balancing swift approvals with affordability creates a pathway toward making essential medications more accessible. Future Implications for Drug Pricing The Trump administration's commitment to affordable drugs also aligns with its broader economic strategies, which include the potential imposition of tariffs on imported pharmaceuticals. Such measures could reshape the industry, underscoring the need for companies to navigate this complex landscape strategically. What This Means for Business Leaders For business leaders and managers in the pharmaceutical sector, understanding these changes is crucial. As the FDA integrates affordability into its approval processes, companies may need to rethink their pricing models and strategies to align with these new guidelines. Embracing this shift presents a unique opportunity to enhance brand reputation and customer trust. As healthcare costs continue to rise, it’s important for industry stakeholders to stay informed on regulatory changes that impact drug pricing and accessibility. Now is the time to lead with empathy and commitment to the communities you serve.

Add Row
Add Element
cropper
update
AI Update - Solutions for Local Business
cropper
update

AI News & Solutions for SMBs in service-based industries (such as plumbing, heating, electricians, roofers, landscaping, etc.) looking to grow or improve efficiency.

  • update
  • update
  • update
  • update
  • update
  • update
  • update
Add Element

COMPANY

  • Privacy Policy
  • Terms of Use
  • Advertise
  • Contact Us
  • Menu 5
  • Menu 6
Add Element

0138 490 1505

AVAILABLE FROM 10AM - 4PM UK

Chesterfield, Derbyshire

United Kingdom

Add Element

ABOUT US

AI Update - Solutions for Local Business is a division of DYLBO digital media, focusing on AI technology for business growth & efficiency.

Add Element

© 2025 Parent Company: DYLBO digital media All Rights Reserved. 4 Cutthorpe Grange, Chesterfield, England S41 9SD . Contact Us . Terms of Service . Privacy Policy

{"company":"Parent Company: DYLBO digital media","address":"4 Cutthorpe Grange","city":"Chesterfield","state":"England","zip":"S41 9SD","email":"support@dylbo.com","tos":"PHA+PHN0cm9uZz48ZW0+V2hlbiB5b3Ugc2lnbi1pbiB3aXRoIHVzLCB5b3UgYXJlIGdpdmluZyZuYnNwOyB5b3VyIHBlcm1pc3Npb24gYW5kIGNvbnNlbnQgdG8gc2VuZCB5b3UgZW1haWwgYW5kL29yIFNNUyB0ZXh0IG1lc3NhZ2VzLiBCeSBjaGVja2luZyB0aGUgVGVybXMgYW5kIENvbmRpdGlvbnMgYm94IGFuZCBieSBzaWduaW5nIGluIHlvdSBhdXRvbWF0aWNhbGx5IGNvbmZpcm0gdGhhdCB5b3UgYWNjZXB0IGFsbCB0ZXJtcyBpbiB0aGlzIGFncmVlbWVudC48L2VtPjwvc3Ryb25nPjwvcD4KCjxwPjxhIGhyZWY9Imh0dHA6Ly93d3cuZ29vZ2xlLmNvbSI+aHR0cDovL3d3dy5nb29nbGUuY29tPC9hPjwvcD4KCjxwPiZuYnNwOzwvcD4KCjxwPjxzdHJvbmc+U0VSVklDRTwvc3Ryb25nPjwvcD4KCjxwPldlIHByb3ZpZGUgYSBzZXJ2aWNlIHRoYXQgY3VycmVudGx5IGFsbG93cyB5b3UgdG8gcmVjZWl2ZSByZXF1ZXN0cyBmb3IgZmVlZGJhY2ssIGNvbXBhbnkgaW5mb3JtYXRpb24sIHByb21vdGlvbmFsIGluZm9ybWF0aW9uLCBjb21wYW55IGFsZXJ0cywgY291cG9ucywgZGlzY291bnRzIGFuZCBvdGhlciBub3RpZmljYXRpb25zIHRvIHlvdXIgZW1haWwgYWRkcmVzcyBhbmQvb3IgY2VsbHVsYXIgcGhvbmUgb3IgZGV2aWNlLiBZb3UgdW5kZXJzdGFuZCBhbmQgYWdyZWUgdGhhdCB0aGUgU2VydmljZSBpcyBwcm92aWRlZCAmcXVvdDtBUy1JUyZxdW90OyBhbmQgdGhhdCB3ZSBhc3N1bWUgbm8gcmVzcG9uc2liaWxpdHkgZm9yIHRoZSB0aW1lbGluZXNzLCBkZWxldGlvbiwgbWlzLWRlbGl2ZXJ5IG9yIGZhaWx1cmUgdG8gc3RvcmUgYW55IHVzZXIgY29tbXVuaWNhdGlvbnMgb3IgcGVyc29uYWxpemF0aW9uIHNldHRpbmdzLjwvcD4KCjxwPllvdSBhcmUgcmVzcG9uc2libGUgZm9yIG9idGFpbmluZyBhY2Nlc3MgdG8gdGhlIFNlcnZpY2UgYW5kIHRoYXQgYWNjZXNzIG1heSBpbnZvbHZlIHRoaXJkIHBhcnR5IGZlZXMgKHN1Y2ggYXMgU01TIHRleHQgbWVzc2FnZXMsIEludGVybmV0IHNlcnZpY2UgcHJvdmlkZXIgb3IgY2VsbHVsYXIgYWlydGltZSBjaGFyZ2VzKS4gWW91IGFyZSByZXNwb25zaWJsZSBmb3IgdGhvc2UgZmVlcywgaW5jbHVkaW5nIHRob3NlIGZlZXMgYXNzb2NpYXRlZCB3aXRoIHRoZSBkaXNwbGF5IG9yIGRlbGl2ZXJ5IG9mIGVhY2ggU01TIHRleHQgbWVzc2FnZSBzZW50IHRvIHlvdSBieSB1cy4gSW4gYWRkaXRpb24sIHlvdSBtdXN0IHByb3ZpZGUgYW5kIGFyZSByZXNwb25zaWJsZSBmb3IgYWxsIGVxdWlwbWVudCBuZWNlc3NhcnkgdG8gYWNjZXNzIHRoZSBTZXJ2aWNlIGFuZCByZWNlaXZlIHRoZSBTTVMgdGV4dCBtZXNzYWdlcy4gV2UgZG8gbm90IGNoYXJnZSBhbnkgZmVlcyBmb3IgZGVsaXZlcnkgb2YgZW1haWwgb3IgU01TLiBUaGlzIGlzIGEgZnJlZSBzZXJ2aWNlIHByb3ZpZGVkIGJ5IHVzLiBIb3dldmVyLCBwbGVhc2UgY2hlY2sgd2l0aCB5b3VyIGludGVybmV0IHNlcnZpY2UgcHJvdmlkZXIgYW5kIGNlbGx1bGFyIGNhcnJpZXIgZm9yIGFueSBjaGFyZ2VzIHRoYXQgbWF5IGluY3VyIGFzIGEgcmVzdWx0IGZyb20gcmVjZWl2aW5nIGVtYWlsIGFuZCBTTVMgdGV4dCBtZXNzYWdlcyB0aGF0IHdlIGRlbGl2ZXIgdXBvbiB5b3VyIG9wdC1pbiBhbmQgcmVnaXN0cmF0aW9uIHdpdGggb3VyIGVtYWlsIGFuZCBTTVMgc2VydmljZXMuIFlvdSBjYW4gY2FuY2VsIGF0IGFueSB0aW1lLiBKdXN0IHRleHQgJnF1b3Q7U1RPUCZxdW90OyB0byZuYnNwOzxoaWdobGlnaHQgY2xhc3M9ImNvbXBhbnlTTVNQaG9uZVVwZGF0ZSI+MDc3MTQwMjYyMjQ8L2hpZ2hsaWdodD4uIEFmdGVyIHlvdSBzZW5kIHRoZSBTTVMgbWVzc2FnZSAmcXVvdDtTVE9QJnF1b3Q7IHRvIHVzLCB3ZSB3aWxsIHNlbmQgeW91IGFuIFNNUyBtZXNzYWdlIHRvIGNvbmZpcm0gdGhhdCB5b3UgaGF2ZSBiZWVuIHVuc3Vic2NyaWJlZC4gQWZ0ZXIgdGhpcywgeW91IHdpbGwgbm8gbG9uZ2VyIHJlY2VpdmUgU01TIG1lc3NhZ2VzIGZyb20gdXMuPC9wPgoKPHA+PHN0cm9uZz5ZT1VSIFJFR0lTVFJBVElPTiBPQkxJR0FUSU9OUzwvc3Ryb25nPjwvcD4KCjxwPkluIGNvbnNpZGVyYXRpb24gb2YgeW91ciB1c2Ugb2YgdGhlIFNlcnZpY2UsIHlvdSBhZ3JlZSB0bzo8L3A+Cgo8b2w+Cgk8bGk+cHJvdmlkZSB0cnVlLCBhY2N1cmF0ZSwgY3VycmVudCBhbmQgY29tcGxldGUgaW5mb3JtYXRpb24gYWJvdXQgeW91cnNlbGYgYXMgcHJvbXB0ZWQgYnkgdGhlIFNlcnZpY2UmIzM5O3MgcmVnaXN0cmF0aW9uIGZvcm0gKHN1Y2ggaW5mb3JtYXRpb24gYmVpbmcgdGhlICZxdW90O1JlZ2lzdHJhdGlvbiBEYXRhJnF1b3Q7KSBhbmQ8L2xpPgoJPGxpPm1haW50YWluIGFuZCBwcm9tcHRseSB1cGRhdGUgdGhlIFJlZ2lzdHJhdGlvbiBEYXRhIHRvIGtlZXAgaXQgdHJ1ZSwgYWNjdXJhdGUsIGN1cnJlbnQgYW5kIGNvbXBsZXRlLiBJZiB5b3UgcHJvdmlkZSBhbnkgaW5mb3JtYXRpb24gdGhhdCBpcyB1bnRydWUsIGluYWNjdXJhdGUsIG5vdCBjdXJyZW50IG9yIGluY29tcGxldGUsIG9yIHdlIGhhdmUgcmVhc29uYWJsZSBncm91bmRzIHRvIHN1c3BlY3QgdGhhdCBzdWNoIGluZm9ybWF0aW9uIGlzIHVudHJ1ZSwgaW5hY2N1cmF0ZSwgbm90IGN1cnJlbnQgb3IgaW5jb21wbGV0ZSwgd2UgaGF2ZSB0aGUgcmlnaHQgdG8gc3VzcGVuZCBvciA8c3Ryb25nPjxzcGFuIHN0eWxlPSJjb2xvcjojRkYwMDAwOyI+dGVybWluYXRlIHlvdXIgYWNjb3VudC9wcm9maWxlIGFuZCByZWZ1c2UgYW55IGFuZCBhbGwgY3VycmVudCBvciBmdXR1cmUgdXNlIG9mIHRoZSBTZXJ2aWNlIChvciBhbnkgcG9ydGlvbiB0aGVyZW9mKS48L3NwYW4+PC9zdHJvbmc+PC9saT4KPC9vbD4KCjxwPiZuYnNwOzwvcD4KPGhpZ2hsaWdodCBjbGFzcz0iY29tcGFueU5hbWVVcGRhdGUiPlBhcmVudCBDb21wYW55OiBEWUxCTyBkaWdpdGFsIG1lZGlhPC9oaWdobGlnaHQ+PGJyIC8+CjxoaWdobGlnaHQgY2xhc3M9ImNvbXBhbnlBZGRyZXNzVXBkYXRlIj40IEN1dHRob3JwZSBHcmFuZ2UsIENoZXN0ZXJmaWVsZCwgRW5nbGFuZCBTNDEgOVNEPC9oaWdobGlnaHQ+PGJyIC8+CjxoaWdobGlnaHQgY2xhc3M9ImNvbXBhbnlQaG9uZVVwZGF0ZSI+MDEzOCA0OTAgMTUwNTwvaGlnaGxpZ2h0PjxiciAvPgo8aGlnaGxpZ2h0IGNsYXNzPSJjb21wYW55RW1haWxVcGRhdGUiPnN1cHBvcnRAZHlsYm8uY29tPC9oaWdobGlnaHQ+","privacy":"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"}

Terms of Service

Privacy Policy

Core Modal Title

Sorry, no results found

You Might Find These Articles Interesting

T
Please Check Your Email
We Will Be Following Up Shortly
*
*
*